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The purpose of this study was to determine 
whether physiologic doses of epinephrine reverse 
the electrophysiologic effects of quinidine in pa- 
tients with an accessory atrioventricular (AV) con- 
nection. Eighteen patients with an accessory AV 
connection who had inducible sustained orthodro- 
mic tachycardia underwent an electrophysiologic 
study in the baseline state and after at least 2 days 
of treatment with 1.4 to 1.9 g/day of quinidine glu- 
conate. The effects of epinephrine were then deter- 
mined. Epinephrine infusion rates of 25 and 50 ngl 
kg/min were used in 9 patients each because these 
doses of epinephrine previously have been demon- 
strated to result in elevated plasma epinephrine 
concentrations in the range that occurs during a va- 
riety of stresses in humans. Quinidine prolonged re- 
fractoriness in the atrium and accessory AV con- 
nection and slowed conduction through the acces- 
sory AV connection. These effects were partially or 
completely reversed by epinephrine. Among 8 pa- 
tients in whom quinidine resulted in orthodromic 
tachycardia becoming noninducible or nonsus- 
tained, sustained tachycardia became inducible 
again in 5 patients after infusion of epinephrine. 
After quinidine, atrial fibrillation was either non- 
inducible or nonsustained in 8 patients; however, 
sustained atrial fibrillation could be induced in 4 of 
these patients after infusion of epinephrine. The re- 
sults of this study demonstrate that the therapeutic 
effect of quinidine in patients who have an accesso- 
ry AV connection are often reversed by physiologic 
increases in circulating epinephrine. 
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B eta-adrenergic stimulation with isoproterenol has been demonstrated to accelerate paroxysmal su- praventricular tachycardia’ and to antagonize the 
therapeutic effects of antiarrhythmic drugs in patients 
with the Wolff-Parkinson-White syndrome.2-6 How- 
ever, because isoproterenol is not produced endogenous- 
ly, the physiologic significance of the response to isopro- 
terenol in quantitative terms is unclear. In contrast to 
isoproterenol, epinephrine is produced endogenously and 
prior studies have determined that infusions of 25 and 
50 ng/kg/min result in elevations of the plasma epi- 
nephrine concentration within a physiologic range.738 
This study determines the effects of physiologic doses of 
epinephrine in patients with an accessory atrioventricu- 
lar (AV) connection and symptomatic tachycardias 
treated with quinidine. 
METHODS 
Patients studied: Eighteen patients with an accesso- 
ry AV connection underwent an electrophysiologic 
study because of recurrent, symptomatic tachycardia. A 
criterion for inclusion in this study was the ability to 
induce orthodromic reciprocating tachycardia in the 
baseline state. There were 15 men and 3 women, with a 
mean age of 40 f 18 years (& standard deviation). 
None had any evidence of structural heart disease. Six- 
teen patients had overt ventricular preexcitation and 2 
patients had a concealed accessory AV connection. The 
accessory AV connection was located in the left free 
wall in 14 patients, in the right free wall in 2 patients 
and in the posterior septum in 2 patients. 
Electrophysiologic study: Electrophysiologic studies 
were performed in the fasting, unsedated state after 
informed consent had been obtained and at least 5 
half-lives after all antiarrhythmic medications had 
been discontinued. The study protocol was approved by 
the Human Research Committee at the University of 
Michigan. Multiple quadripolar electrode catheters 
were positioned within the heart using conventional 
techniques. Leads Vi, I and III, and the intracardiac 
electrograms recorded at the right atrium, His bundle 
position, coronary sinus and right ventricular apex were 
displayed on an oscilloscope and recorded at a paper 
speed of 100 mm/s on a Siemens-Elema Mingograf 7 
recorder. Pacing was performed with a programmable 
stimulator (Bloom Associates) using stimuli 2 ms in du- 
ration and twice the late diastolic threshold. 
Electrophysiologic parameters measured: The AV 
nodal (AH) and infranodal (HV) conduction times 
were determined at an atria1 paced cycle length of 500 
and 600 ms. The minimum atria1 and ventricular pacing 
cycle lengths associated with 1:l AV and ventriculoatri- 
al conduction through the accessory AV connection 
were determined by incremental pacing in steps of 10 
ms. Refractory periods were measured using 8 beat 
drive trains at a cycle length of 500 ms and a single 
extrastimulus scanned in steps of 10 ms. Orthodromic 
reciprocating tachycardia was induced in each patient, 
and the cycle length and AH, HV and VA intervals 
during tachycardia were measured. The ventriculoatrial 
interval was determined using the low right atria1 septal 
electrogram. 
The effect of epinephrine on atria1 fibrillation was 
not determined systematically in this study because of 
time constraints and in order to avoid patient discom- 
fort and the need for direct current countershock. How- 
ever, atria1 fibrillation was induced either purposely or 
inadvertently before and after the administration of epi- 
nephrine in 8 patients, and in these patients the mean 
cycle length and the shortest cycle length between 2 
consecutive preexcited QRS complexes were measured. 
Induced tachycardias were considered nonsustained 
if there was spontaneous termination within 30 seconds 
and sustained if the duration was > 30 seconds. 
Infusion of epinephrine: The infusion rates of epi- 
nephrine used in this study were 25 and 50 ng/kg/min. 
These infusion rates were used because previous studies 
have demonstrated that these doses result in elevations 
in the plasma epinephrine concentration comparable to 
a variety of stresses in humans.7J 
After measurement of baseline electrophysiologic 
parameters, 25 ng/kg/min of epinephrine was infused 
in 8 patients to determine the effects of epinephrine in 
the absence of quinidine. Prior studies have found that 
10 minutes are required to obtain a steady-state plasma 
epinephrine concentration, 9,10 therefore, the infusion 
was continued for 14 minutes to ensure that a steady- 
state concentration had been reached before remeasure- 
ment of the electrophysiologic parameters. 
In each of the 18 patients, electrophysiologic param- 
eters were measured in the baseline state and after at 
least 2 days of treatment with 1.4 to 1.9 g/day of quini- 
dine gluconate (mean daily dose 1.7 f 0.2 g). Immedi- 
ately after measurement of quinidine’s effects, epineph- 
rine was infused at a rate of 25 or 50 ng/kg/min in 9 
patients each. The plasma quinidine concentration im- 
mediately after measurement of quinidine’s electrophys- 
iologic effects was 3.0 f 1.2 mg/liter, and 2.9 f 1.1 
mg/liter after measurement of epinephrine’s effects. 
The elapsed time between these 2 determinations of the 
plasma quinidine concentration was 24 to 30 minutes. 
Analysis of data: The effects of epinephrine in the 
absence of quinidine were analyzed using a paired t test. 
The effects of quinidine and quinidine plus epinephrine 
on each variable were analyzed using a repeated mea- 
sures analysis of variance. l l The effects of the 2 doses of 
epinephrine were compared also using a repeated mea- 
sures analysis of variance. Multiple comparisons were 
performed using Fisher’s least significant difference 
procedure. ” A mixed model analysis of variance was 
- 
TABLE I Effects of 25 ng/kg/min of Epinephrine in the 
Absence of Quinidine in 8 Subjects 
Baseline Epinephrine p Value 
Sinus cycle length (ms) 972 * 163* 708f91 <O.OOl 
MAP (mm Hg) 99f 11 1032~10 NS 
AH (ms)t Ill+25 86f13 <O.Ol 
HV (ms)t 4f32 28+ 17 <0.05 
Atrial ERP (ms) 199 f 16 184* 15 <O.OOl 
Atrial FRP (ms) 245 f 13 231 f 14 <O.Ol 
1:l AV conduction (ms)* 286 f 29 273 f 23 co.05 
AAVC ERP (ms) 290 f 14 275f21 NS 
I:1 VA conduction (ms)* 290 f 38 262 f 33 <0.05 
Retrograde AAVC ERP (ms) 277 f 28 273i35 NS 
Orthodromic tachycardia 
Cycle length (ms) 359 f 36 333 f 30 <O.OOl 
AH (ms) 160f35 139 f 31 <O.OOl 
HV (ms) 42?c5 4Of5 NS 
VA (ms) 158 L!Z 34 154+30 NS 
* Mean f standard deviation. 
+ Measured during atrial pacing at the same cycle length (500 or 6120 ms). 
*Shortest pacing cycle length associated with 1:l conduction through the accesso- 
ry AV connection. 
AAVC = accessory atrioventricular conduction; AV = atrioventricular; ERP = effec- 
tive refractory period; FRP = functional refractory period; MAP = mean atria pres- 
sure; NS = not significant; VA = ventriculoatrial. 
used to analyze the data for the variables that had miss- 
ing data.12 A p value <0.05 was considered significant. 
RESULTS 
Effects of epinephrine in the absence of quinidine: 
A 25 ng/kg/min infusion of epinephrine resulted in a 
significant decrease in the mean sinus cycle length, AH 
interval, atria1 refractory periods and the shortest pac- 
ing cycle length associated with 1:l AV and ventriculo- 
atria1 conduction through the accessory AV connection. 
The mean HV interval increased because of shortening 
of the AH interval and a lesser degree of ventricular 
preexcitation. Measurement of the antegrade effective 
refractory period of the accessory AV connection before 
and after epinephrine was often limited by atria1 refrac- 
toriness and was possible in only 2 patients; in these 2 
patients, the effective refractory period shortened by 10 
to 20 ms. 
The mean orthodromic tachycardia cycle length de- 
creased from 359 f 36 to 333 f 30 ms. During ortho- 
dromic tachycardia, the AH interval decreased signili- 
cantly, whereas the HV and AV intervals were un- 
changed by epinephrine (Table I). 
In 3 patients, the mean cycle length and the shortest 
cycle length between 2 consecutive preexcited QRS 
complexes during atria1 fibrillation decreased from 362 
f 21 and 238 f 19 ms, respectively, to 320 f 14 and 
216 f 16 ms during infusion of epinephrine (p <0.05). 
Electrophysiologic effects of quinidine and epineph- 
rine: Quinidine resulted in a significant increase in the 
shortest pacing cycle length associated with I:1 conduc- 
tion in the accessory AV connection and a lengthening 
of refractory periods of the atrium and accessory AV 
connection. 
The mean dose of epinephrine in the 9 patients who 
received the 25 ng/kg/min infusion of epinephrine was 
2.2 f 0.6 pg/min, and 4.1 f 0.7 pg/min in the 9 pa- 
tients who received the 50 ng/kg/min infusion of epi- 
nephrine. The electrophysiologic effects of the 2 infu- 
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TABLE II Effects of Quinidine and Quinidine Plus Epinephrine in 18 Subjects I 
p Values 
B Q Q&E QvsB Q&EvsQ Q&EvsB 
Sinus cycle length (ms) 798f 179” 790f 154 661 f 93 NS <O.Ol <O.OOl 
MAP (mm Hg) 96i 12 94f8 9Ozkll NS NS <0.05 
AH (ms)t 104 f 28 lllf22 88i18 NS <O.OOl <0.05 
HV (ms)t 7i30 11 f26 18&27 NS NS <0.05 
Atrial ERP (ms) 197 zk 19 230 f 22 201 f 23 <a001 <O.OOl NS 
Atrial FRP (ms) 241 f 19 278 f 29 253 rt 27 <O.cQl <O.oOl <0.05 
1:l AV conduction (ms)* 268 f 29 345 f 75 298 2~ 56 <O.OOl <O.OOl <O.Ol 
AAVC ERP (ms) 276 f 18 316 f 46 280 f 31 <O.Ol <O.Ol NS 
I:1 VA conduction (ms)* 279 f 49 369 f 82 312i65 <O.OOl <0.001 <O.Ol 
Retrograde AAVC ERP (ms) 264 f 38 363 f 64 316f56 <O.oal <O.Ol <O.Ol 
* Mean +Z standard deviation. 
T  Measured during atrial pacing at the same cycle length (500 or 600 ms). 
*Shortest pacing cycle length associated with 13 conduction through the accessory AV connection. 
B = baseline; Q = quinidine; other abbreviations as in Table I. 
TABLE Ill Effects of Epinephrine on the Induction of Orthodromic Tachycardia in 8 Patients in Whom Quinidine Suppressed the 
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*The tachycardia was sustained in each patient in the baseline state. 
t Maximum duration on multiple induction attempts. 
CL = cycle length: Epi = epinephrine. 
sion rates of epinephrine were not significantly different 
and therefore the results are presented in combined’ 
fashion (Table II). All of quinidine’s electrophysiologic 
effects were completely or partially reversed by epi- 
nephrine. 
Effects of quinidine and epinephrine on orthodromic 
tachycardia: The effects of the 2 doses of epinephrine 
on orthodromic tachycardia were similar and therefore 
the results are presented in combined fashion. Quinidine 
lengthened the mean orthodromic tachycardiac cycle 
length from 337 f 51 to 389 f 48 ms (p <O.OOl). Epi- 
nephrine resulted in a shortening of the mean tachycar- 
dia cycle length to 340 f 43 (p >0.05 ms vs baseline), 
indicating complete reversal of quinidine’s effects on 
tachycardia cycle length. The changes in mean tachy- 
cardia cycle length that occurred with quinidine and 
epinephrine were associated with concomitant signifi- 
cant changes in the mean AH interval during tachycar- 
dia, but not in the HV or ventriculoatrial intervals. 
Sustained orthodromic tachycardia no longer was in- 
ducible in 8 patients after treatment with quinidine. 
However, when epinephrine was infused, sustained or- 
thodromic tachycardia again became inducible in 5 of 
these patients (Table III). 
Effects of quinidine and epinephrine on atrial fibril- 
lation: The effects of epinephrine were determined in 
patients who had either noninducible (4) or nonsus- 
tained (4) atria1 fibrillation after treatment with quini- 
dine. The mean cycle length and the shortest cycle 
length between 2 consecutive preexcited QRS complex- 
es during atria1 fibrillation were 365 f 28 and 242 f 19 
ms, respectively, after quinidine. These values shortened 
to 343 f 13 and 228 f 16 ms, respectively, after the 
addition of epinephrine (p <0.05 for each). Among the 
4 patients with noninducible atria1 fibrillation, atria1 fi- 
brillation became sustained or nonsustained in 1 patient 
each after the infusion of epinephrine. Among the 4 pa- 
tients with nonsustained atria1 fibrillation, the atria1 fi- 
brillation became sustained in 3 after the infusion of 
epinephrine. 
DISCUSSION 
The results of this study demonstrate that elevation 
of the plasma epinephrine concentration to levels with- 
in the range that occurs during a variety of stresses in 
humans may reverse the electrophysiologic effects of 
quinidine in patients with symptomatic tachycardias in- 
volving an accessory AV connection. Although plasma 
epinephrine concentrations were not measured in the 
present study, prior studies have determined the plasma 
epinephrine concentrations that result from infusion of 
the same doses of epinephrine under similar conditions 
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used in this study.‘,* The 25 ng/kg/min infusion of epi- 
nephrine increases the plasma epinephrine concentra- 
tion to levels within the range that occurs during ciga- 
rette smoking,13 public speaking,t4 submaximal exer- 
cise,’ mild hypoglycemia, l3 dental extraction,15 and 
surgery.16 A 50 ng/kg/min infusion of epinephrine in- 
creases the plasma epinephrine concentration to levels 
within the range that occurs during maximal exercise,’ 
acute myocardial infarction,“~‘* diabetic ketoacidosis13 
and severe hypoglycemia. l3 Therefore quinidine’s thera- 
peutic effects in patients who have an accessory AV 
connection may be markedly attenuated by physiologic 
and pathophysiologic increases in circulating epineph- 
rine. 
Electrophysiologic effects of epinephrine: Both in 
the absence and presence of quinidine, epinephrine sig- 
nificantly shortened the refractory periods of the acces- 
sory AV connection and atrium and accelerated con- 
duction through the accessory AV connection. Because 
the majority of patients in this study had overt ventricu- 
lar preexcitation, the electrophysiologic effects of epi- 
nephrine on the AV node-His-Purkinje axis could not 
be studied in a systematic fashion. However, a prior 
study demonstrated that epinephrine also shortens re- 
fractoriness and accelerates conduction in the AV 
node.* 
There were no significant differences in the effects 
of the 2 infusion rates of epinephrine used in this study. 
This may indicate that the relation between the epi- 
nephrine dose and its electrophysiologic effects may not 
be monotonic. However, it also is possible that a signifi- 
cant difference in the effects of the 2 infusion rates 
would have been demonstrated had the sample sizes 
been larger. 
During the period of time that the effects of epi- 
nephrine were determined, the mean quinidine plasma 
concentration fell only slightly from 3.0 f 1.2 to 2.9 f 
1.1 mg/liter. Therefore, it is unlikely that the reversal of 
quinidine’s effects during infusion of epinephrine was 
related to a time-dependent decrease in quinidine’s tis- 
sue effects. 
Effects of epinephrine on orthodromic tachycardia 
and atrial fibrillation: As would be expected given epi- 
nephrine’s effects on conduction through the accessory 
AV connection and the normal conduction pathway, the 
effect of epinephrine on orthodromic tachycardia was to 
accelerate its rate and to reverse completely the length- 
ening of the tachycardia cycle length that occurred with 
quinidine. 
Of note is that quinidine resulted in orthodromic 
tachycardia becoming either noninducible or nonsus- 
tained in 8 of 18 patients in this study. However, with 
the addition of epinephrine, sustained tachycardia be- 
came inducible again in 5 of these 8 patients. In addi- 
tion, in the subset of patients in whom the effects of the 
epinephrine on atria1 fibrillation were determined, epi- 
nephrine accelerated the ventricular rate and often fa- 
cilitated the induction of sustained atria1 fibrillation. 
These results indicate that although quinidine may be 
effective in suppressing orthodromic tachycardia or atri- 
al fibrillation in the electrophysiology laboratory, its ef- 
ficacy may be lost when patients are exposed to a 
heightened degree of sympathetic activation. 
Prior studies with isoproterenol: No prior studies 
have examined the interaction between epinephrine and 
antiarrhythmic drugs in patients with an accessory AV 
connection. However, there have been prior studies of 
the effects of isoproterenol in patients with the Wolff- 
Parkinson-White syndrome treated with various antiar- 
rhythmic drugs. Similar to the interaction between epi- 
nephrine and quinidine in the present study, isoprotere- 
no1 often reversed the therapeutic effects of amiodarone, 
flecainide and encainide.=m6 
Mechanism of epinephrine’s effects: Loss of antiar- 
rhythmic drug efficacy in response to isoproterenol in 
prior studies- suggests that the reversal of quinidine’s 
electrophysiologic effects by epinephrine in the present 
study was related to the fl-adrenergic stimulation prop- 
erties of epinephrine. However, it was beyond the scope 
of the present study to determine whether epinephrine’s 
effects in the presence of quinidine were mediated solely 
by ,&receptor stimulation, by a specific interaction at 
sites of quinidine binding or by some other mechanism. 
Limitations: This study has 2 principal limitations. 
First, the effects of quinidine and epinephrine on atria1 
fibrillation were determined in only 6 of the 16 patients 
in this study who had overt ventricular preexcitation. In 
the other 10 patients the effects of epinephrine on atri- 
al fibrillation were not determined in order to avoid 
lengthy studies, hemodynamically unstable atria1 fibril- 
lation or the need for general anesthesia and direct cur- 
rent countershock to terminate atria1 fibrillation. 
A second limitation of the study is that no meaning- 
ful follow-up data are available to determine whether 
the response to epinephrine in the electrophysiology Iab- 
oratory may have correlated with clinical recurrences of 
tachycardia during periods of sympathetic activation. 
This was because most patients elected to undergo ei- 
ther surgical or catheter ablation of their accessory AV 
connection. 
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